There was a big loophole described in this acx blog post allowing people to get cheaper GLP-1 as long as the big pharmas were experiencing shortage problems. Basically the compounding pharmas were a lot cheaper, 200$ vs 1000$ per month.
It’s looking like that shortage is going away. What will happen to people like me (no insurance, no diabetes, needed for weight loss but no longer obese, basically vanity users)
1,000
3.00🏅 Top traders
| # | Name | Total profit |
|---|---|---|
| 1 | Ṁ1,849 | |
| 2 | Ṁ373 | |
| 3 | Ṁ142 | |
| 4 | Ṁ113 | |
| 5 | Ṁ86 |
@ian I need a huge if else statement. I think this is like shortage goes away but the loophole continues
The title is based on a fundamentally flawed premise. Tirzepatide injection is no longer in shortage according to FDA. Semaglutide is still listed as in shortage. So is dulaglutide, liraglutide, etc. So “ozempic” is not actually affected. You will need to be much clearer about which glp-1s you will be considering for this, and how many need to be out of shortage before you consider the “loophole” gone.